Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M Booster Vaccine Trial in Burkinabe School Children
NCT07074665Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of R21/Matrix-M in malaria, sponsored by University of Oxford. Started Feb 2026; status: active, not recruiting.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07074665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074665.